Method for decreasing skeletal muscle damage and/or oxidative stress in mammals

Patent metadata

Field	Value
Publication number	US-10016382-B2
Application number	US-201514736775-A
Country	US
Kind code	B2
Filing date	Jun 11, 2015
Priority date	Jun 12, 2014
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmaceutical or drug products. After physical activity the L-carnitine supplement can lower myoglobin, TBARS, and creatine kinase in the bloodstream.

First claim

What is claimed:

1. A method for decreasing skeletal muscle damage and/or oxidative stress during and after intense physical activity of an active canine, the method comprising administering to the active canine that is and/or has undergone physical activity that lasts at least 20 minutes and increases a heart rate from about 5% to about 150% or more of a resting heart rate and results in an intensity equivalent to at least 50% of the active canine's VO 2 max, an effective amount of an L-carnitine supplement, and wherein the L-carnitine is administered to the active canine in an amount from about 50 to about 250 mg per day.

2. A method as defined in claim 1 , wherein the L-carnitine supplement is administered without administering an amino acid supplement.

3. A method as defined in claim 1 , wherein the L-carnitine supplement is administered at least every one to three days.

4. A method as defined in claim 1 , wherein the L-carnitine supplement is administered daily.

5. A method as defined in claim 1 , wherein L-carnitine is administered to the active canine in an amount from 30 milligrams to 250 milligrams per dose.

6. A method as defined in claim 1 , wherein the L-carnitine supplement is administered orally.

7. A method as defined in claim 1 , wherein the L-carnitine supplement is combined with a food composition and administered to the active canine.

8. A method as defined in claim 1 , wherein the L-carnitine supplement comprises a solid.

9. A method as defined in claim 1 , wherein the L-carnitine supplement is administered to the active canine in an amount sufficient to inhibit increases in myoglobin amounts in blood after activity.

10. A method as defined in claim 1 , wherein the L-carnitine supplement is administered to the active canine in an amount sufficient to lower a fractional breakdown rate (FBR) in muscle samples and in an amount sufficient to increase lean mass.

11. A method as defined in claim 1 , wherein myoglobin amounts in blood are reduced by greater than 50% after activity in comparison to an active canine that is and/or has undergone the same physical activity that has not received the L-carnitine supplement.

12. A method as defined in claim 1 , wherein the L-carnitine supplement is administered in an amount sufficient reduce thiobarbituric acid reactive substances amounts in blood by greater than 50% after activity in comparison to an active canine that is and/or has undergone the same physical activity that has not received the L-carnitine supplement.

13. A method as defined in claim 1 , wherein thiobarbituric acid reactive substances amounts in blood are reduced by greater than 75% after activity in comparison to an active canine that is and/or has undergone the same physical activity that has not received the L-carnitine supplement.

14. A method as defined in claim 1 , wherein the L-carnitine supplement is administered in an amount sufficient to reduce peroxidation of membranes due to physical stress.

15. A method as defined in claim 1 , wherein the L-carnitine supplement is administered in an amount sufficient to decrease skeletal muscle damage and to decrease oxidative stress during and after physical activity.

16. A method as defined in claim 1 , wherein the L-carnitine supplement comprises a liquid.

17. A method as defined in claim 1 , wherein L-carnitine is administered to the active canine in an amount greater than about 2.0 mg/kg body weight per day to about 9.0 mg/kg body weight per day.

Assignees

• Lonza Ag

Inventors

• Lopez Johnny
• Owen Kevin
• Woodworth Jason
• Coon Craig
• Collings George

Classifications

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A23L33/15

  Vitamins · CPC title